Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the inner ear; and DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
IPO Year: 2021
Exchange: NASDAQ
Website: decibeltx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/15/2023 | $7.00 → $2.00 | Outperform → Market Perform | SVB Securities |
| 12/2/2021 | $25.00 | Buy | JonesTrading |
| 11/15/2021 | $23.00 | Buy | HC Wainwright & Co. |
| 11/10/2021 | $15.00 → $14.00 | Outperform | SVB Leerink |
| 10/22/2021 | $21.00 | Outperform | Robert W. Baird |
| 10/22/2021 | $21.00 | Outperform | Baird |
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
4 - Decibel Therapeutics, Inc. (0001656536) (Issuer)
15-12G - Decibel Therapeutics, Inc. (0001656536) (Filer)
EFFECT - Decibel Therapeutics, Inc. (0001656536) (Filer)
S-8 POS - Decibel Therapeutics, Inc. (0001656536) (Filer)
S-8 POS - Decibel Therapeutics, Inc. (0001656536) (Filer)
S-8 POS - Decibel Therapeutics, Inc. (0001656536) (Filer)
POS AM - Decibel Therapeutics, Inc. (0001656536) (Filer)
8-K - Decibel Therapeutics, Inc. (0001656536) (Filer)
SC 14D9/A - Decibel Therapeutics, Inc. (0001656536) (Subject)
25-NSE - Decibel Therapeutics, Inc. (0001656536) (Subject)
SC TO-T/A - Decibel Therapeutics, Inc. (0001656536) (Subject)
SVB Securities downgraded Decibel Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $7.00 previously
JonesTrading initiated coverage of Decibel Therapeutics with a rating of Buy and set a new price target of $25.00
HC Wainwright & Co. initiated coverage of Decibel Therapeutics with a rating of Buy and set a new price target of $23.00
SVB Leerink reiterated coverage of Decibel Therapeutics with a rating of Outperform and set a new price target of $14.00 from $15.00 previously
Robert W. Baird initiated coverage of Decibel Therapeutics with a rating of Outperform and set a new price target of $21.00
Baird initiated coverage of Decibel Therapeutics with a rating of Outperform and set a new price target of $21.00
SVB Leerink reiterated coverage of Decibel Therapeutics with a rating of Outperform and set a new price target of $18.00 from $26.00 previously
SVB Leerink initiated coverage of Decibel Therapeutics with a rating of Outperform and set a new price target of $26.00
Barclays initiated coverage of Decibel Therapeutics with a rating of Overweight and set a new price target of $30.00
BMO Capital Markets initiated coverage of Decibel Therapeutics with a rating of Outperform and set a new price target of $30.00
- Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to expand the Phase 1/2 clinical trial to the U.K. and Spain in patients two years of age and younger - - Initiated manufacturing activities to support IND-enabling studies for our AAV.103 product candidate designed to restore hearing in individuals with mutations in the GJB2 gene - BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing
BOSTON, March 21, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Matthew Kapusta to its Board of Directors. "We are pleased to welcome Matt to the Decibel Board. He is an accomplished life sciences executive who has played a key role in advancing gene therapy products from the laboratory to patients in need," said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. "Matt's appointment to the Board provides us with a critical strategic perspective, as we continue to build Decibel and lead
- Received clearance from US FDA for IND and from UK MHRA for CTA to initiate CHORD™, a global Phase 1/2 dose escalation clinical trial of DB-OTO in pediatric patients - - Plan to initiate the CHORD™ trial in the First Half of 2023 - - Presented key non-clinical data at the 46th Annual ARO MidWinter Meeting supporting compelling safety profile of DB-OTO and preclinical data supporting selection of AAV.103 product candidate - BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial result
- Received FDA Clearance of IND Application for DB-OTO, Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss - - Announced Submission of CTAs for DB-OTO in the United Kingdom and Spain - - Expect to Initiate a Phase 1/2 Clinical Trial of DB-OTO in the First Half of 2023 - - Plan to Identify AAV.103 Product Candidate in the Fourth Quarter of 2022- BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the third quarter ended
BOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Kevin F. McLaughlin to its Board of Directors. "We are pleased to welcome Kevin to the Decibel Board. He brings a wealth of biopharma experience, including guiding biotech companies through stages of increasing financial and operational maturity," said Laurence Reid, Ph.D., Chief Executive Officer at Decibel. "His appointment to the Board provides us with a critical strategic perspective as we continue to build a sustainable ge
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of Cynthia Hu, J.D., as Chief Legal Officer and Corporate Secretary. "Cynthia brings to Decibel more than 20 years of strategy, operations and legal experience, including 15 years in the life sciences industry. She joins us at a critical juncture as we pursue our long-term ambition to build a leading biotech company focused on hearing and balance disorders," said Laurence Reid, Ph.D., Chief Executive Officer of Decibel. Ms. Hu join
BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of William (Bill) H. Carson, M.D., as Chairman of the Board of Directors. Dr. Carson, a board-certified psychiatrist, brings over 20 years of experience in the biopharmaceutical industry. He was most recently the President and CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), leading the development and regulatory approvals of Otsuka's global compounds, including Abilify Maintena®, Rexulti®, Samsca® and Jynarq
BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced the appointment of leading experts in gene therapy, cochlear development and molecular genetics to its Scientific Advisory Board (SAB). "These additions to our SAB bring a deep understanding of the genetic roots of hearing loss and balance disorders, and we look forward to working closely with them as we progress our pipeline of gene therapies and regenerative medicines," said Joe Burns, Ph.D., Vice President, Discovery. "We value their insights and
NEW YORK, Aug. 12, 2023 (GLOBE NEWSWIRE) -- Western Asset Mortgage Capital Corporation (NYSE:WMC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of WMC to AG Mortgage Investment Trust, Inc. Under the terms of the proposed merger, WMC shareholders will receive 1.5 shares of AG Mortgage Investment Trust, Inc. for each share of WMC common stocked owned and a cash payment from Angelo Gordon equal to approximately 9.99% of the aggregate per share merger consideration (not to exceed $7 million in total). If you are a WMC investor, and would like additional information about our investigation, please complete the Information R
- Activated CHORDTM clinical trial sites in U.S., U.K. and Spain and commenced patient screening activities; anticipate dosing first patient in the Phase 1/2 clinical trial in the second half of 2023 - - Received FDA Breakthrough Therapy Designation for DB-020 for protection against hearing loss associated with cisplatin chemotherapy - - Announced on August 9 definitive agreement for Regeneron Pharmaceuticals to acquire Decibel - BOSTON, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financi
Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel's lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Decibel Therapeutics, Inc. (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced a definitive agreement for the acquisition of
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 12:45 p.m. E.T in New York, NY. A live webcast of the presentation may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company's website for approximately 90 days following the fir
BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago, Illinois, June 2-6, 2023. The Company will present a poster summarizing data from the interim analysis of the Phase 1b clinical trial of DB-020, a novel, proprietary formulation of sodium thiosulfate (STS) designed to protect against hearing loss in cancer patients receiving cisplatin chemotherapy. "Hearing loss and tinnitus are significa
BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Barclays 2023 Gene Editing and Gene Therapy Summit on Wednesday, May 24, 2023 at 10:30 a.m. E.T being held virtually. A live webcast of the presentation may be accessed by visiting the Investors section of the Decibel Therapeutics website at https://ir.decibeltx.com. An archived replay of the webcast will be available on the Company's website for approximate
- Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for CHORD to expand the Phase 1/2 clinical trial to the U.K. and Spain in patients two years of age and younger - - Initiated manufacturing activities to support IND-enabling studies for our AAV.103 product candidate designed to restore hearing in individuals with mutations in the GJB2 gene - BOSTON, May 15, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing
BOSTON, May 12, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced approval of its Clinical Trial Application (CTA) by the Spanish Agency of Medicines and Medical Devices (AEMPS) to initiate a Phase 1/2 clinical trial in pediatric patients of DB-OTO, its lead gene therapy product candidate. DB-OTO is being developed in collaboration with Regeneron Pharmaceuticals, Inc. and is a cell-selective, adeno-associated virus (AAV) gene therapy product candidate designed to provide durable, physiological hearing in individuals
BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held in Los Angeles, California May 16 – 20th, 2023. The Company will deliver podium presentations on its lead gene therapy product candidate, DB-OTO, a gene therapy designed to provide hearing to individuals with hearing loss caused by mutations of the otoferlin gene, and its AAV.103 product candidate, a gene therapy designed to restore hearing
- Decibel intends to initiate a Phase 1/2 clinical trial of DB-OTO in patients with congenital hearing loss caused my mutations of the otoferlin gene in the first half of 2023 - - There are currently no approved pharmacologic treatment options for individuals with otoferlin-related hearing loss - BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (NASDAQ:DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that the European Medicines Agency (EMA) Committee on Orphan Medicinal Products (COMP) has issued a positive opinion on orphan drug designation for DB-OTO
SC 13G/A - Decibel Therapeutics, Inc. (0001656536) (Subject)
SC 13D/A - Decibel Therapeutics, Inc. (0001656536) (Subject)
SC 13D - Decibel Therapeutics, Inc. (0001656536) (Subject)
SC 13G/A - Decibel Therapeutics, Inc. (0001656536) (Subject)
SC 13G - Decibel Therapeutics, Inc. (0001656536) (Subject)
SC 13G - Decibel Therapeutics, Inc. (0001656536) (Subject)
SC 13G/A - Decibel Therapeutics, Inc. (0001656536) (Subject)
SC 13G - Decibel Therapeutics, Inc. (0001656536) (Subject)